Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Glycemic control is the mainstay of preventing diabetes complications at the expense of increased risk of hypoglycemia. Severe hypoglycemia negatively impacts the quality of life of patients with type 1 diabetes and can lead to morbidity and mortality. Currently available glucagon emergency kits are effective at treating hypoglycemia when correctly used, however use is complicated especially by untrained persons. Better formulations and devices for glucagon treatment of hypoglycemia are needed, specifically stable liquid glucagon. Out of the scope of this review, other potential uses of stable liquid glucagon include congenital hyperinsulinism, post–bariatric surgery hypoglycemia, and insulinoma induced hypoglycemia. In the 35 years since Food and Drug Administration (FDA) approval of the first liquid stable human recombinant insulin, we continue to wait for the glucagon counterpart. For mild hypoglycemia, a commercially available liquid stable glucagon would enable more widespread implementation of mini-dose glucagon use as well as glucagon in dual hormone closed-loop systems. This review focuses on the current and upcoming pharmaceutical uses of glucagon in the treatment of type 1 diabetes with an outlook on stable liquid glucagon preparations that will hopefully be available for use in patients in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 1×
“Treatment of mild hypoglycemia requires consumption of extra calories; 16 g of glucose tabs contain 60 kcal, which is a significant downside for the greater than 50% of adults with type 1 diabetes that are overweight or obese.(14) Severe hypoglycemia is an episode requiring external assistance for recovery.”
BackgroundCryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 3×
“Patients with type 1 diabetes average two episodes of symptomatic hypoglycemia per week.(10) Treatment of mild hypoglycemia requires consumption of extra calories; 16 g of glucose tabs contain 60 kcal, which is a significant downside for the greater than 50% of adults with type 1 diabetes that are overweight or obese.”
BackgroundHypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411 · cited 1×
“Exercise leads to decreased epinephrine response to hypoglycemia, also contributing to recurrent hypoglycemia.(8) Negative Effects of Hypoglycemia”
BackgroundA Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose
Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.146647 · Cited by 250 · cited 1×
“Intranasal medication administration, with its needle free design, is effective for use by bystanders in other emergency situations.(27) Intranasal glucagon results in lower blood glucagon concentrations than intramuscular glucagon, however clinically relevant glucose raising effects are similar to injection despite t…”
BackgroundNovel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Self-citationHaidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
Barendse, S., Singh, H., Frier, B. M., & Speight, J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03416.x · Cited by 161
Jacobs, P. G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12707 · Cited by 116 · cited 1×
“To date, research studies of dual hormone closed-loop systems have used lyophilized glucagon preparations that are typically reconstituted every 24 hours to fill the pump reservoirs.(39,40,54) In order to be used in closed-loop systems, glucagon will need to have stability in a liquid state at 37°C for at least 3-7 da…”
BackgroundSelf-citationHövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115 · cited 1×
“0 mg dose.(57) To date, data suggest similar side effect profile to conventional glucagon with mild injection site reactions and dose dependent nausea and vomiting.”
BackgroundYale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88 · cited 2×
“4 minutes.(26) Real-world use of intranasal glucagon is likely to be more cumbersome, especially in situations where the person is combative or having a seizure.”
BackgroundMini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes
Rickels, M. R., DuBose, S. N., Toschi, E., Beck, R. W., Verdejo, A. S., Wolpert, H., Cummins, M. J., Newswanger, B., Riddell, M. C., T1D Exchange Mini-Dose Glucagon Exercise Study Group, et al. (2018) · Diabetes Care · doi:10.2337/dc18-0051 · Cited by 79 · cited 1×
“Mini-dose glucagon also shows promise in preventing exercise-induced hypoglycemia in adults.(37) The main adverse events reported with mini-dose glucagon are nausea and vomiting which are rare and dose dependent.”
BackgroundHaymond, M. W., DuBose, S. N., Rickels, M. R., Wolpert, H., Shah, V. N., Sherr, J. L., Weinstock, R. S., Agarwal, S., Verdejo, A. S., Cummins, M. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00591 · Cited by 42 · cited 2×
“A recent study showed comparable efficacy of 150 μg of subcutaneous glucagon to 16 g of glucose tabs to treat hypoglycemia in an ambulatory setting.(36) With blood sugars 50-69 mg/ dl, the clinically judged efficacy was 94% for glucagon versus 95% for glucose tabs.”
Background
Cited by
Hofland, J., Falconi, M., Christ, E., Castaño, J. P., Faggiano, A., Lamarca, A., Perren, A., Petrucci, S., Prasad, V., Ruszniewski, P., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13318 · Cited by 259
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Novel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Pontiroli, A. E., & Tagliabue, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01483-y · Cited by 25
Metadata
- Authors
- Wilson, L. M., & Castle, J. R.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2018-02-08
- Volume
- 12
- Issue
- 4
- Pages
- 847-853
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2792527295
- Cited by
- 63
- References
- 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.